Impact of pharmaceutical care on patients with type 1 diabetes mellitus seen through the judical actions.
Not Applicable
- Conditions
- Insulin-dependent diabetes mellitus
- Registration Number
- RBR-5g9wfg
- Lead Sponsor
- niversidade Federal de São João Del Rei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patientes with type 1 diabetes mellitus, who obtain their insulines through judical actions.
Exclusion Criteria
Bedridden patients who can not attend the place of pharmaceutical consultations.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A reduction in the levels of glycated hemoglobin, fasting glycemia, triglycerides, total cholesterol, and fractions is expected to be achieved verified through laboratory tests over a period of one year.<br><br>;We expect to see a reduction in drug costs, medical consultations and hospitalizations, verified through a reduction of these parameters, within a year.
- Secondary Outcome Measures
Name Time Method It is expected to observe a reduction in the number of drugs judicialized for the treatment of type 1 diabetes mellitus in a period of one year, which will be verified by comparing the number of medicines judicialized before and after the intervention.